Boxer Capital Management’s Cullinan Therapeutics CGEM Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q3
$6.91M Buy
+450,000
New +$8.62M 0.6% 24
2025
Q1
– Sell
-907,895
Closed -$11.1M – 34
2024
Q4
$11.1M Hold
907,895
– – 0.94% 29
2024
Q3
$15.2M Buy
907,895
+250,000
+38% +$4.43M 0.75% 37
2024
Q2
$11.5M Buy
+657,895
New +$14M 0.6% 41
2023
Q4
– Sell
-1,074,082
Closed -$9.7M – 56
2023
Q3
$9.7M Hold
1,074,082
– – 0.52% 41
2023
Q2
$11.6M Hold
1,074,082
– – 0.54% 46
2023
Q1
$11M Hold
1,074,082
– – 0.54% 42
2022
Q4
$11.3M Hold
1,074,082
– – 0.6% 42
2022
Q3
$13.8M Hold
1,074,082
– – 0.77% 40
2022
Q2
$13.8M Hold
1,074,082
– – 0.87% 39
2022
Q1
$11.2M Hold
1,074,082
– – 0.58% 42
2021
Q4
$16.6M Hold
1,074,082
– – 0.64% 36
2021
Q3
$24.2M Hold
1,074,082
– – 0.85% 34
2021
Q2
$27.7M Hold
1,074,082
– – 0.98% 28
2021
Q1
$44.8M Buy
+1,074,082
New +$43.6M 1.52% 18

Other funds holding CGEM

Boxer Capital Management's CGEM Position: Q3 2026 in Review

Boxer Capital Management opened a new position in Cullinan Therapeutics (CGEM) in Q3 2026: 450,000 shares worth $6.91M. The stake represents 0.6% of the portfolio and ranks #24 among its holdings. This is a return to the name: Boxer Capital Management previously reported a position in CGEM as recently as Q4 2024.

Boxer Capital Management first reported a position in CGEM in Q1 2021 and has held it in 15 quarters since. The position peaked at $44.8M in Q1 2021. 182 funds tracked by Wall St. Rank hold CGEM as of Q3 2026.

  • Boxer Capital Management held 450,000 shares of Cullinan Therapeutics worth $6.91M as of Q3 2026.
  • Cullinan Therapeutics was a new Boxer Capital Management position in Q3 2026.
  • Cullinan Therapeutics made up 0.6% of Boxer Capital Management's portfolio in Q3 2026, its #24 holding.
  • Boxer Capital Management first reported a position in Cullinan Therapeutics in Q1 2021 and has held it in 15 quarters since.
  • Boxer Capital Management's Cullinan Therapeutics position peaked at $44.8M in Q1 2021.
  • 182 funds tracked by Wall St. Rank held Cullinan Therapeutics as of Q3 2026.

Based on Boxer Capital Management's 13F filing for Q3 2026, filed 16 Nov 2026.